Expert disagreements, alternative perspectives, and minority opinions.
The direction of MOTS-c change in obesity is actively disputed — earlier studies show decreases while newer data shows increases, suggesting the relationship is more complex than a simple linear decline.
“Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation.”
Editorial Context
Most studies report that circulating MOTS-c levels are reduced in obese individuals. However, more recent research explicitly contradicts this, finding increased levels in obese adults associated with metabolic dysregulation. A meta-analysis noted that while some obese participants had higher levels, the general trend in metabolically adapted patients was dampened MOTS-c response.
Detail
This contradiction has significant implications for therapeutic use. If MOTS-c is already elevated in obesity as a compensatory mechanism, exogenous supplementation could overshoot and cause metabolic disruption rather than correction. The conflicting data may reflect differences in study populations, disease stage, or measurement methodology.
Fundamental disagreement exists over whether MOTS-c is highly unstable or reasonably stable under refrigeration, calling into question both product viability and the reliability of research measurements.
“MOTS-c reconstituted in water remained stable with no significant degradation for at least 30 days when stored at 4°C.”
Editorial Context
One analysis describes MOTS-c as extremely unstable, losing 25% of its concentration at 4°C in just 24 hours. A separate study by Mohtashami et al. found the opposite — no significant degradation for at least 30 days at the same temperature. This contradiction directly affects practical handling, storage, and the viability of commercial products.
Detail
This discrepancy may stem from differences in peptide formulation, reconstitution media, purity of starting material, or measurement methodology. The practical stakes are high: if the instability claim is correct, most commercially available MOTS-c may be degraded; if the stability claim holds, cold-chain products could be viable. Neither study has been definitively reconciled.
MOTS-c may simultaneously promote and inhibit cellular aging depending on tissue type, undermining the simple narrative that it is universally anti-aging.
“MOTS-c levels increased following the induction of senescence and treatment promoted pro-inflammatory cytokines associated with SASP.”
Editorial Context
In cultured human fibroblasts, MOTS-c appears pro-senescent — levels rise after senescence induction and the peptide promotes inflammatory SASP cytokines. In pancreatic beta-cells, the opposite occurs: MOTS-c declines in senescent cells and treatment protects against senescence. Researchers acknowledge these effects may be context-dependent based on cell type.
Detail
This cell-type-dependent duality is a serious challenge for therapeutic application. If MOTS-c promotes senescence in fibroblasts (skin, connective tissue) while protecting pancreatic cells, systemic administration could accelerate aging in some tissues while benefiting others. The 'context dependent' qualifier suggests the field does not yet understand the governing variables.
Contradictory documents exist about elamipretide's regulatory status — it is simultaneously FDA-approved for Barth syndrome and described as unapproved research-only, reflecting the gap between narrow orphan drug approval and broader off-label promotion.
“SS-31 is currently only available as a research peptide.”
Editorial Context
In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide/SS-31) as the first treatment for Barth syndrome — the first approved mitochondria-targeted therapeutic. However, a separate patient information document claims SS-31 is only available as a research peptide and includes standard FDA non-evaluation disclaimers.
Detail
This contradiction likely reflects the difference between the approved indication (Barth syndrome only) and the much broader off-label market. The patient information document may predate the approval or may be describing the peptide's status for indications other than Barth syndrome. This ambiguity creates risk for consumers who may conflate narrow FDA approval with broad safety endorsement.